home / stock / trxc / trxc news


TRXC News and Press, TransEnterix Inc. From 05/08/19

Stock Information

Company Name: TransEnterix Inc.
Stock Symbol: TRXC
Market: NYSE
Website: transenterix.com

Menu

TRXC TRXC Quote TRXC Short TRXC News TRXC Articles TRXC Message Board
Get TRXC Alerts

News, Short Squeeze, Breakout and More Instantly...

TRXC - Notable earnings after Thursday's close

AAXN , AGO , AIRG , AL , ALRM , ALTR , AMBC , AMBR , AMPH , AQN , ASYS , BGNE , BKNG , CABO , CARG , CISN , CORT , CTRL , CUTR , DBX , EFX , ELY , EQH , FGEN , FLY , FSCT , GH , GLOB , GPRO , GSBD , ICUI , JAG , MAIN , MAXR , MTD , MTW , NDLS , NTR , N...

TRXC - The FDA Might Have Inadvertently Implanted Establishment Labs As The Next Hot Medtech Stock

Establishment Labs Could Become The Next Hot Medtech Growth Stock Establishment Labs ( ESTA ) manufactures and sells medical devices for aesthetic and reconstructive plastic surgery. It primarily offers silicone gel-filled smooth category breast implants under the Motiva Implants brand nam...

TRXC - TransEnterix to Present at the 2019 RBC Capital Markets Global Healthcare Conference

TransEnterix, Inc. (NYSE American:TRXC) announced today that Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will present at the 2019 RBC Capital Markets Global Healthcare Conference at The InterContinental Ne...

TRXC - TransEnterix Schedules First Quarter Financial and Operating Results Conference Call for May 9, 2019

TransEnterix, Inc. (NYSE American: TRXC) announced today that it plans to release first quarter financial and operating results after the market closes on Thursday, May 9, 2019. Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Fi...

TRXC - Conformis Is A Failed Market Experiment, No Justification For Its 400%+ Rally - $0.50 Price Target

We Found No Fundamental Justification For CFMS 400% Rally We at White Diamond Research are medical device experts. Recently, we have been exposing medical device companies that have inferior devices. Over the last eight months, we have published on Seeking Alpha bearish reports on the follow...

TRXC - Week 14 Breakout Forecast: Short-Term Picks To Give You An Edge

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years including 98 weeks of public weekly selections as part of this ongoing live forward-testing. In 2017, the sample size began with 12 stocks, then 8 stocks in...

TRXC - TransEnterix to Showcase Digital Laparoscopy with the Senhance Surgical System at Society of American Gastrointestinal and Endoscopic Surgeons 2019 Annual Meeting

TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery (MIS), today announced it will host several events highlighting digital laparoscopy with the Senhance™ Surgical Syste...

TRXC - Why Hospitals Are Not Buying The T2 Biosystems Diagnostic System - $1.50 1-Year Price Target

T2 Biosystems (TTOO) T2 Magnetic Resonance ("MR") technology, powered through their T2Dx Instrument, is a diagnostic system that can do a variety of blood tests from inserted panels. They just had a big launch in mid-2018 for the T2Bacteria which got FDA approved in May 2018 that was suppose...

TRXC - Week 10 Breakout Forecast: Short-Term Picks To Give You An Edge

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on winning breakout selections over more than 5 years including 94 weeks of public weekly selections as part of this ongoing live forward-testing. Breakout Stock Portfolio 2019 results YTD All time total...

TRXC - TransEnterix, Inc. (TRXC) CEO Todd Pope on Q4 2018 Results - Earnings Call Transcript

TransEnterix, Inc. (TRXC) Q4 2018 Earnings Conference Call February 26, 2019 08:00 ET Company Participants Mark Klausner - Investor Relations Todd Pope - President and Chief Executive Officer Joe Slattery - Executive Vice President and Chief Financial Officer Conference Call ...

Previous 10 Next 10